Search results
Results from the WOW.Com Content Network
The American Kidney Fund's grant programs help low-income dialysis patients to access health care, including dialysis and transplantation. AKF provides grants that help with health insurance premiums and other treatment necessities not covered by health insurance, such as transportation to dialysis, nutritional products and emergency assistance.
The initiative stated three explicit goals: to ensure that 80 percent of patients newly diagnosed with kidney failure would either receive a transplant or at-home dialysis by 2025; to reduce the instances of kidney failure by one fourth by 2030; to make twice as many kidneys available for transplant by 2030. [5]
In 1972 the United States Congress passed legislation authorizing the End Stage Renal Disease Program (ESRD) under Medicare. Section 299I of Public Law 92-603, passed on October 30, 1972, extended Medicare coverage to Americans if they had stage five chronic kidney disease (CKD) and were otherwise qualified under Medicare's work history ...
AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as kidney stones or blood clots, low blood pressure, or heart disease. It ...
Home hemodialysis (HHD) is the provision of hemodialysis to purify the blood of a person whose kidneys are not working normally, in their own home. One advantage to doing dialysis at home is that it can be done more frequently and slowly, which reduces the "washed out" feeling and other symptoms caused by rapid ultrafiltration, and it can often be done at night, while the person is sleeping.
Hemodialysis, also spelled haemodialysis, or simply dialysis, is a process of filtering the blood of a person whose kidneys are not working normally. This type of dialysis achieves the extracorporeal removal of waste products such as creatinine and urea and free water from the blood when the kidneys are in a state of kidney failure.
In the context of chronic kidney disease, they are more accurately viewed as life-extending treatments, although if chronic kidney disease is managed well with dialysis and a compatible graft is found early and is successfully transplanted, the clinical course can be quite favorable, with life expectancy of many years.
FDA staff reviewers raised concerns over unclear benefits of Ardelyx's drug for kidney disease patients, but the company's shares are up on expectations over a possible approval.